Jan Brancewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Brancewicz has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Ilona Marszalek
Cellis AG, Zurich, Switzerland
4 shared publicationsBartlomiej Taciak
Cellis AG, Zurich, Switzerland
3 shared publicationsKonrad Gabrusiewicz
Cellis AG, Zurich, Switzerland
3 shared publicationsMagdalena Krol
Cellis AG, Zurich, Switzerland
3 shared publications- Magdalena Król
Center of Cellular Immunotherapies, Warsaw University of Life Sciences, 02-786 Warsaw, Poland
3 shared publications Tomasz Rygiel
Cellis AG, Zurich, Switzerland
3 shared publications
Latest Publications
- Open Access
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1679271
Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
Macrophages, the most abundant immune cells in many solid tumors, are no longer viewed solely as accomplices of cancer but as powerful therapeutic allies. This review charts the rapid rise of macrophage-based immunotherapies, from CD47/SIRPα checkpoint blockade and CAR-macrophages to macrophage-drug conjugates (MDCs). We emphasize emerging frontiers - RNA-based reprogramming, epigenetic modulation, small activating RNA and circRNA approaches, and macrophage-derived extracellular vesicles - that are redefining how tumor-associated macrophages can be targeted or harnessed. Distinct from earlier TAM reviews, we integrate outcomes from ongoing and completed clinical trials, highlight therapeutic platforms beyond classical depletion and polarization, and frame macrophages not only as targets but also as delivery vehicles. By spotlighting both innovative strategies and the challenges of moving them into the clinic, we aim to provide a forward-looking guide for researchers and clinicians shaping the next generation of cancer immunotherapy.
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1679271
Open AccessEmerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
Macrophages, the most abundant immune cells in many solid tumors, are no longer viewed solely as accomplices of cancer but as powerful therapeutic allies. This review charts the rapid rise of macrophage-based immunotherapies, from CD47/SIRPα checkpoint blockade and CAR-macrophages to macrophage-drug conjugates (MDCs). We emphasize emerging frontiers - RNA-based reprogramming, epigenetic modulation, small activating RNA and circRNA approaches, and macrophage-derived extracellular vesicles - that are redefining how tumor-associated macrophages can be targeted or harnessed. Distinct from earlier TAM reviews, we integrate outcomes from ongoing and completed clinical trials, highlight therapeutic platforms beyond classical depletion and polarization, and frame macrophages not only as targets but also as delivery vehicles. By spotlighting both innovative strategies and the challenges of moving them into the clinic, we aim to provide a forward-looking guide for researchers and clinicians shaping the next generation of cancer immunotherapy.
- Open Access
Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.
Open AccessImmunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.
- 18 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (803) , eadr4058
Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models
The treatment of solid tumors faces substantial hurdles because of inadequate drug delivery and the immunosuppressive tumor microenvironment. To address these challenges, we developed a therapeutic platform using macrophages loaded with ferritin-drug conjugates, referred to as macrophage-drug conjugates (MDC), and applied it to glioblastoma, an immunologically cold solid tumor. MDC loaded with ferritin-conjugated monomethyl auristatin E enabled efficient, cell contact–dependent transfer of the payload by a mechanism involving transfer of iron-binding proteins, from either mouse or human macrophages preferentially into glioma cells. This targeted delivery and therapeutic efficacy was demonstrated across in vitro coculture systems, ex vivo assays using dissociated glioblastoma patient tumor samples, and in vivo using orthotopic glioblastoma mouse models, all while maintaining a favorable preclinical safety profile evidenced by minimal systemic toxicity and localized drug biodistribution. Beyond direct tumor cell killing leading to significant tumor regression and prolonged survival in these models, MDC therapy reprogrammed the immunosuppressive tumor microenvironment. Immune profiling by spectral flow cytometry revealed enhanced infiltration and activation of cytotoxic T lymphocytes and B lymphocytes while reducing immunosuppressive regulatory T cells. This culminated in a robust, durable, T cell–dependent antitumor immune response, the necessity of which was confirmed through studies in immunodeficient mouse models and by lymphocyte depletion, and which conferred protection against tumor rechallenge. The combined cytotoxic and immunomodulatory effects highlight the potential of MDC therapy as a promising strategy for glioblastoma treatment and support its further clinical development.
- 18 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (803) , eadr4058
Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models
The treatment of solid tumors faces substantial hurdles because of inadequate drug delivery and the immunosuppressive tumor microenvironment. To address these challenges, we developed a therapeutic platform using macrophages loaded with ferritin-drug conjugates, referred to as macrophage-drug conjugates (MDC), and applied it to glioblastoma, an immunologically cold solid tumor. MDC loaded with ferritin-conjugated monomethyl auristatin E enabled efficient, cell contact–dependent transfer of the payload by a mechanism involving transfer of iron-binding proteins, from either mouse or human macrophages preferentially into glioma cells. This targeted delivery and therapeutic efficacy was demonstrated across in vitro coculture systems, ex vivo assays using dissociated glioblastoma patient tumor samples, and in vivo using orthotopic glioblastoma mouse models, all while maintaining a favorable preclinical safety profile evidenced by minimal systemic toxicity and localized drug biodistribution. Beyond direct tumor cell killing leading to significant tumor regression and prolonged survival in these models, MDC therapy reprogrammed the immunosuppressive tumor microenvironment. Immune profiling by spectral flow cytometry revealed enhanced infiltration and activation of cytotoxic T lymphocytes and B lymphocytes while reducing immunosuppressive regulatory T cells. This culminated in a robust, durable, T cell–dependent antitumor immune response, the necessity of which was confirmed through studies in immunodeficient mouse models and by lymphocyte depletion, and which conferred protection against tumor rechallenge. The combined cytotoxic and immunomodulatory effects highlight the potential of MDC therapy as a promising strategy for glioblastoma treatment and support its further clinical development.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 6174
Abstract 6174: Macrophage-based immunotherapy of platinum-resistant ovarian cancer
Platinum-resistant ovarian cancer remains one of the greatest challenges in oncology, with limited treatment options and poor survival outcomes. To address this unmet need we develop MDC-735, a novel allogeneic, off-the-shelf macrophage-based therapy. MDC-735 leverages the breakthrough TRAIN (TRAnsfer of Iron-binding proteiN) mechanism, discovered by our team, to enable macrophages to deliver drug-loaded ferritin complexes directly to tumor cells. This approach bypasses drug resistance, penetrates hypoxic tumor regions, and overcomes challenges faced by conventional therapies. In preclinical studies, MDC-735 demonstrated remarkable efficacy in multiple solid tumor models, including platinum-resistant ovarian cancer, showing significant tumor shrinkage, long-term animal survival and immune activation. This unique therapy employs allogeneic macrophages loaded with a tubulin polymerization inhibitor, achieving targeted delivery while minimizing systemic toxicity. The ability of MDC-735 to alter the tumor microenvironment and induce immune resistance to recurrence highlights its potential as a game-changing therapy. This innovative therapy promises to transform the landscape of platinum-resistant ovarian cancer treatment, providing a scalable and effective solution for a disease with limited options. Citation Format: Jan Brancewicz, Maciej Bialasek, Bartłomiej Taciak, Ilona Marszalek, Konrad Gabrusiewicz, Tomasz Rygiel, Magdalena Krol. Macrophage-based immunotherapy of platinum-resistant ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6174.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 6174
Abstract 6174: Macrophage-based immunotherapy of platinum-resistant ovarian cancer
Platinum-resistant ovarian cancer remains one of the greatest challenges in oncology, with limited treatment options and poor survival outcomes. To address this unmet need we develop MDC-735, a novel allogeneic, off-the-shelf macrophage-based therapy. MDC-735 leverages the breakthrough TRAIN (TRAnsfer of Iron-binding proteiN) mechanism, discovered by our team, to enable macrophages to deliver drug-loaded ferritin complexes directly to tumor cells. This approach bypasses drug resistance, penetrates hypoxic tumor regions, and overcomes challenges faced by conventional therapies. In preclinical studies, MDC-735 demonstrated remarkable efficacy in multiple solid tumor models, including platinum-resistant ovarian cancer, showing significant tumor shrinkage, long-term animal survival and immune activation. This unique therapy employs allogeneic macrophages loaded with a tubulin polymerization inhibitor, achieving targeted delivery while minimizing systemic toxicity. The ability of MDC-735 to alter the tumor microenvironment and induce immune resistance to recurrence highlights its potential as a game-changing therapy. This innovative therapy promises to transform the landscape of platinum-resistant ovarian cancer treatment, providing a scalable and effective solution for a disease with limited options. Citation Format: Jan Brancewicz, Maciej Bialasek, Bartłomiej Taciak, Ilona Marszalek, Konrad Gabrusiewicz, Tomasz Rygiel, Magdalena Krol. Macrophage-based immunotherapy of platinum-resistant ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6174.
- Top Cited PapersOpen Access
- 27 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 2107
The Multifaceted Role of Macrophages in Biology and Diseases
Macrophages are highly adaptable immune cells capable of responding dynamically to diverse environmental cues. They are pivotal in maintaining homeostasis, orchestrating immune responses, facilitating tissue repair, and, under certain conditions, contributing to disease pathogenesis. This review delves into the complex biology of macrophages, highlighting their polarization states, roles in autoimmune and inflammatory diseases, involvement in cancer progression, and potential as therapeutic targets. By understanding the context-dependent functional plasticity of macrophages, we can better appreciate their contributions to health and disease, paving the way for innovative therapeutic strategies.
- 27 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 2107
Top Cited PapersOpen AccessThe Multifaceted Role of Macrophages in Biology and Diseases
Macrophages are highly adaptable immune cells capable of responding dynamically to diverse environmental cues. They are pivotal in maintaining homeostasis, orchestrating immune responses, facilitating tissue repair, and, under certain conditions, contributing to disease pathogenesis. This review delves into the complex biology of macrophages, highlighting their polarization states, roles in autoimmune and inflammatory diseases, involvement in cancer progression, and potential as therapeutic targets. By understanding the context-dependent functional plasticity of macrophages, we can better appreciate their contributions to health and disease, paving the way for innovative therapeutic strategies.
- Open Access
- 4 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-30
Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism
Treatment of solid tumors remains challenging and therapeutic strategies require continuous development. Tumor-infiltrating macrophages play a pivotal role in tumor dynamics. Here, we present a Macrophage-Drug Conjugate (MDC) platform technology that enables loading macrophages with ferritin-drug complexes. We first show that macrophages actively take up human heavy chain ferritin (HFt) in vitro via macrophage scavenger receptor 1 (MSR1). We further manifest that drug-loaded macrophages transfer ferritin to adjacent cancer cells through a process termed ‘TRAnsfer of Iron-binding protein’ (TRAIN). The TRAIN process requires direct cell-to-cell contact and an immune synapse-like structure. At last, MDCs with various anti-cancer drugs are formulated with their safety and anti-tumor efficacy validated in multiple syngeneic mice and orthotopic human tumor models via different routes of administration. Importantly, MDCs can be prepared in advance and used as thawed products, supporting their clinical applicability. This MDC approach thus represents a promising advancement in the therapeutic landscape for solid tumors.
- 4 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-30
Open AccessHarnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism
Treatment of solid tumors remains challenging and therapeutic strategies require continuous development. Tumor-infiltrating macrophages play a pivotal role in tumor dynamics. Here, we present a Macrophage-Drug Conjugate (MDC) platform technology that enables loading macrophages with ferritin-drug complexes. We first show that macrophages actively take up human heavy chain ferritin (HFt) in vitro via macrophage scavenger receptor 1 (MSR1). We further manifest that drug-loaded macrophages transfer ferritin to adjacent cancer cells through a process termed ‘TRAnsfer of Iron-binding protein’ (TRAIN). The TRAIN process requires direct cell-to-cell contact and an immune synapse-like structure. At last, MDCs with various anti-cancer drugs are formulated with their safety and anti-tumor efficacy validated in multiple syngeneic mice and orthotopic human tumor models via different routes of administration. Importantly, MDCs can be prepared in advance and used as thawed products, supporting their clinical applicability. This MDC approach thus represents a promising advancement in the therapeutic landscape for solid tumors.